Do pasireotide and MK-677 have opposite effects on growth hormone?

Pasireotide is a somatostatin analog that suppresses hormone secretion in its labeled disease settings. MK-677 stimulates GH release. Their indications, study populations and endpoints differ.

Is pasireotide FDA approved while MK-677 is not?

Pasireotide products have specific FDA-labeled uses for acromegaly and Cushing's disease. There is no FDA-approved ibutamoren product.

Does MK-677 improve strength in older adults?

A 65-person trial increased fat-free mass but found no significant strength or function improvement; it was too small and short to rule out a functional effect.

Can these drugs be ranked or combined from the cited evidence?

No head-to-head or combination outcome trial cited here supports a clinical ranking, compatibility judgment or combination benefit.

Pasireotide vs MK-677: Indications and Evidence

Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.

Different clinical questions

Pasireotide is an FDA-approved somatostatin analog with specific labeled uses in acromegaly and Cushing’s disease. MK-677 (ibutamoren) is an oral nonpeptide growth hormone secretagogue with no FDA-approved product. Opposite effects on parts of the GH axis do not make these treatments alternatives for the same patient or establish a safety ranking. FDA Signifor LAR label; FDA ibutamoren evaluation.

Question	Pasireotide	MK-677
Evidence context	Labeled treatment in selected pituitary diseases	Investigational trials in different populations
GH-axis action	Somatostatin-receptor signaling suppresses secretion in relevant disease settings	Ghrelin-receptor agonism stimulates GH release
FDA status	Approved for specific labeled indications	No approved ibutamoren product
Glucose caution	Label warns of hyperglycemia and diabetes	Older-adult trial found higher fasting glucose and lower insulin sensitivity

In a randomized 65-person trial of healthy older adults, MK-677 raised GH, IGF-1 and fat-free mass, but did not significantly improve strength, function or abdominal visceral fat. The trial was insufficiently powered and too short to rule out a functional effect. It does not estimate efficacy or adverse-event rates relative to pasireotide. Nass et al., PMID 18981485.

The pasireotide label’s glucose warnings concern patients treated for its approved diseases; the MK-677 finding concerns healthy older adults. Comparing the severity or frequency of these effects across those unlike studies would be misleading. FDA Signifor LAR label.

Ibutamoren remains in pediatric development as LUM-201: official Phase 3 NCT06948214 was recruiting in the September 29, 2026 archive. Development is not approval or evidence for the labeled pasireotide diseases. FDA ibutamoren review.

No cited head-to-head or combination trial establishes a ranking or treatment strategy. This page makes no use recommendation.

Pasireotide vs MK-677

Pasireotide

MK-677

Different clinical questions

View Full Dossiers

Stay Updated on Peptide Comparisons